CA Stock MarketDetailed Quotes
INNO InnoCan Pharma Corp
- 0.230
- +0.005+2.22%
15min DelayMarket Closed Nov 15 09:30 ET
65.71MMarket Cap-10952P/E (TTM)
0.230High0.230Low500Volume0.230Open0.225Pre Close115.00Turnover0.41052wk High0.00%Turnover Ratio285.69MShares0.18552wk Low-0.021EPS TTM50.98MFloat Cap1.650Historical HighLossP/E (Static)221.67MShs Float0.050Historical Low-0.023EPS LYR0.00%Amplitude--Dividend TTM9.58P/B1Lot Size--Div YieldTTM
InnoCan Pharma Corp Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 194.67%675K | 35.71%-747K | 35.65%-3.9M | 3.89%-1.31M | 47.17%-718K | 59.63%-713K | 26.36%-1.16M | 8.48%-6.07M | 42.01%-1.36M | -0.89%-1.36M |
| Net income from continuing operations | 340.81%956K | -18.40%-1.45M | -9.23%-4.25M | 31.97%-796K | -1,020.86%-1.83M | 78.27%-397K | -68.45%-1.23M | 61.46%-3.89M | -93.39%-1.17M | 95.51%-163K |
| Operating gains losses | -13,112.50%-1.06M | 41.67%-42K | 109.30%258K | -33.84%-265K | 155.07%603K | 98.37%-8K | 92.72%-72K | -220.19%-2.77M | 89.09%-198K | -158.37%-1.1M |
| Depreciation and amortization | 11.11%10K | 42.86%10K | -5.71%33K | -38.46%8K | 125.00%9K | 80.00%9K | -46.15%7K | -18.60%35K | 0.00%13K | -60.00%4K |
| Remuneration paid in stock | 519.67%378K | 769.17%1.16M | -11.69%854K | -26.12%99K | 248.45%561K | -71.36%61K | -71.02%133K | -55.29%967K | -65.90%134K | -73.86%161K |
| Other non cashItems | ---- | -145.00%-9K | -106.40%-8K | -108.06%-10K | ---- | ---- | 120.20%20K | 250.60%125K | 247.62%124K | --0 |
| Change In working capital | 186.30%315K | -1,754.55%-408K | -49.34%-793K | -29.65%-293K | 65.65%-113K | -242.02%-365K | 90.56%-22K | 45.20%-531K | 8.13%-226K | -8.94%-329K |
| -Change in receivables | 521.84%541K | -522.99%-542K | -307.36%-338K | -486.84%-147K | -365.28%-191K | -51.67%87K | 31.50%-87K | 135.05%163K | 114.50%38K | 141.86%72K |
| -Change in inventory | 56.30%-59K | -470.00%-855K | 0.81%-616K | 60.49%-64K | -22.48%-267K | 30.05%-135K | -212.50%-150K | -686.08%-621K | -852.94%-162K | -1,190.00%-218K |
| -Change in payables and accrued expense | -296.67%-595K | 360.00%989K | 320.55%161K | 19.61%-82K | 197.27%178K | -155.56%-150K | 470.69%215K | 82.82%-73K | -409.09%-102K | -22.00%-183K |
| Interest paid (cash flow from operating activities) | ---- | ---- | ---- | ---- | -25.40%47K | ---- | ---- | ---- | ---- | -26.74%63K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 194.67%675K | 35.71%-747K | 35.65%-3.9M | 3.89%-1.31M | 47.17%-718K | 59.63%-713K | 26.36%-1.16M | 8.48%-6.07M | 42.01%-1.36M | -0.89%-1.36M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 70.00%-3K | 94.12%-2K | -170.97%-84K | 43.75%-9K | -933.33%-31K | -900.00%-10K | -209.09%-34K | 35.42%-31K | -128.57%-16K | 92.68%-3K |
| Net PPE purchase and sale | 70.00%-3K | 92.59%-2K | -76.92%-46K | 18.18%-9K | --0 | -900.00%-10K | -145.45%-27K | 36.59%-26K | ---11K | 92.68%-3K |
| Net other investing changes | ---- | ---- | -660.00%-38K | --0 | ---32K | --1K | ---7K | 28.57%-5K | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 66.67%-3K | 94.12%-2K | -170.97%-84K | 43.75%-9K | -966.67%-32K | -800.00%-9K | -209.09%-34K | 35.42%-31K | -128.57%-16K | 92.68%-3K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 16.67%-5K | 306.16%1.45M | 2,233.60%2.92M | 56,000.00%1.12M | 1,159.13%1.45M | -125.00%-6K | 3,075.00%357K | -99.18%125K | -100.03%-2K | -95.73%115K |
| Net issuance payments of debt | 16.67%-5K | 16.67%-5K | -100.00%-22K | -150.00%-5K | -225.00%-5K | -400.00%-6K | 60.00%-6K | 71.05%-11K | 77.78%-2K | 140.00%4K |
| Net common stock issuance | --0 | 196.17%619K | --1.56M | --584K | --762K | --0 | --209K | --0 | --0 | --0 |
| Proceeds from stock option exercised by employees | --0 | 442.86%836K | 917.65%1.38M | --539K | 522.52%691K | --0 | 5,033.33%154K | -98.81%136K | --0 | -95.90%111K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 16.67%-5K | 306.16%1.45M | 2,233.60%2.92M | 56,000.00%1.12M | 1,159.13%1.45M | -125.00%-6K | 3,075.00%357K | -99.18%125K | -100.03%-2K | -95.73%115K |
| Net cash flow | ||||||||||
| Beginning cash position | 12.37%4.6M | -21.47%3.89M | -55.22%4.95M | -37.28%4.02M | -56.34%3.37M | -57.17%4.09M | -55.22%4.95M | 372.54%11.05M | 9.38%6.42M | 66.37%7.73M |
| Current changes in cash | 191.62%667K | 183.55%701K | 82.07%-1.07M | 85.38%-202K | 155.97%698K | 58.23%-728K | 47.60%-839K | -169.24%-5.97M | -127.15%-1.38M | -195.34%-1.25M |
| Effect of exchange rate changes | -708.33%-73K | 147.37%9K | 107.03%9K | 172.41%63K | 25.40%-47K | 115.38%12K | -119.00%-19K | -252.38%-128K | -194.57%-87K | 26.74%-63K |
| End cash Position | 53.84%5.19M | 12.37%4.6M | -21.47%3.89M | -21.47%3.89M | -37.28%4.02M | -56.34%3.37M | -57.17%4.09M | -55.22%4.95M | -55.22%4.95M | 9.38%6.42M |
| Free cash from | 192.95%672K | 37.01%-749K | 35.17%-3.95M | 4.00%-1.32M | 47.28%-718K | 59.08%-723K | 25.17%-1.19M | 8.65%-6.09M | 41.54%-1.38M | 1.87%-1.36M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
CA
Overall
Symbol
Latest Price
% Chg
No Data